Poland: impact of a no-deal Brexit scenario on biocidal products’ data changes, and the validity of parallel import licences for medicinal products

Published date02 April 2019
Law FirmHogan Lovells
AuthorAgnieszka Majka
Subject MatterMarketing,Medical Devices,Life Sciences,Manufacturers,Biotechnology,Imports,Regulatory Standards,Trade Policy,Licensing Rules,Poland,UK Brexit,Pharmaceutical Industry,No-Deal Brexit

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT